Live · updated just now

Trauma therapy results smaller in people also taking psychiatric medicines

Tuesday, 17 November 2026 · Mental health & wellbeing · Full report · Evidence: Moderate

What was found

In a large group of adults treated for post-traumatic stress disorder (PTSD), intensive trauma-focused psychotherapy brought a sizable drop in symptoms overall. On a standard clinician-rated PTSD scale (the CAPS-5), scores fell by an average of 25.7 points 1. People who were also taking psychiatric medication during therapy improved somewhat less than those who were not. Their gain was 2.52 points smaller, which works out to about 9.4% less benefit, and this gap was still present at a check six months later 1. The weaker results were seen consistently with antidepressants as a group and with several specific drugs: amitriptyline, mirtazapine and fluoxetine. They were also seen with anticonvulsants, antipsychotics, and the sleep medicines zolpidem and zopiclone 1.

Who it applies to

The findings come from adults with long-lasting or delayed-onset PTSD who received intensive trauma-focused therapy at a specialized psychotrauma center in the Netherlands 1. They may not carry over to other settings, other forms of therapy, or other groups of patients.

How strong the evidence is

Moderate. This was a prospective cohort study of 6,125 adults, 1,382 of whom were taking psychiatric medication alongside therapy 1. To mimic a trial as closely as possible, the researchers used statistical methods designed to reduce bias, namely target trial emulation, double machine learning and inverse probability weighting 1. Even so, patients were not randomly assigned to take or not take medication. Other differences between the two groups could still explain part of the result. The study also did not establish why these medicines might weaken the effect of therapy 1. This summary is based on the abstract only, because the full text is not openly available.

What it means in practice

The study suggests that some psychiatric medicines taken during intensive trauma-focused therapy may reduce how much people benefit from it 1. The authors do not conclude that these medicines should be stopped. They note that stopping medication can carry risks, such as withdrawal effects or a return of symptoms 1. They call for clinical trials to test whether tapering or switching these medicines before therapy is safe and leads to better results 1. Until such trials are done, the finding points to a question that needs answering rather than a settled answer.